You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

36 search results for: disease background

expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

5 min

Dermatology

Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.

expert video

Can early intervention modify the course of AD?

5 min

Dermatology

Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.

expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview

8 min

Dermatology

Watch ADVENT now: Dermatologist Mark Koh describes the Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children.

expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children

9 min

Dermatology

Highlights from the ADVENT WCD 2023 symposium delving into the pathophysiology and management of atopic dermatitis in children.

expert video

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis

26 min

Dermatology

Highlights from the 2023 WCD ADVENT symposium, exploring practical considerations for the management of atopic dermatitis in children.

expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview (Copy)

8 min

Dermatology

Watch ADVENT now: Dermatologist Mark Koh describes the Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children.

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region